Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NTRS$171.90+1.55(+0.91%)Northern Trust Celebrates 30 Years in Singapore[10:00:00 PM ET]JELD$1.36-0.05(-3.55%)JELD-WEN Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 4.875% Senior Notes due 2027 JELD-WEN Holding, Inc. (NYSE: JELD) ("JELD-WEN" or the "Company") today announced that JELD-WEN, Inc. (the "Issuer") commenced an offer to (x) all...[9:51:00 PM ET]CWT$47.15-0.67(-1.40%)California Water Service Group Reports Solid Third Quarter 2026 Results and Successful Execution of Business Strategy[9:15:00 PM ET]EMAT$1.71+0.28(+19.39%)StreetWatch: Evolution Metals Brings Eight-Grade Magnet Portfolio to the U.S. Army's Drone Supply Search[8:30:00 PM ET]BHAVU$10.17-0.04(-0.44%)BHAV Acquisition Corp II Announces Pricing of $100 Million Initial Public Offering[8:30:00 PM ET]MESO$15.03+1.85(+14.04%)Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)[8:19:57 PM ET]ELEK$0.00+0.00(+10.26%)Lithium, Location & Long-Term Vision: Elektros INC. (OTC:ELEK) Eyes an American Supply-Chain Opportunity[8:17:00 PM ET]FFMFF$0.900.00(0.00%)Study confirms FireFly on track to be a significant copper producer[8:03:23 PM ET]RNECF$19.41+2.07(+11.94%)Renesas Reports Financial Results for the Third Quarter Ended September 30, 2026[8:00:00 PM ET]RNECF$19.41+2.07(+11.94%)Renesas Announces Consolidated Forecasts[8:00:00 PM ET]ELEK$0.00+0.00(+10.26%)The Next Chapter in American Lithium: Elektros (OTC:ELEK) Spotlights a Potential New York Opportunity[8:00:00 PM ET]

AMRN · NASDAQ

Amarin Corporation plc

$12.78 -0.09 (-0.77%)

Company overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$264M
Employees
275
Headquarters
Dublin
Website
amarincorp.com
CEO
Aaron D. Berg
Listed
April 1, 1993
P/E
-7.90
Dividend yield
0.00%

Company financials

Revenue
$215M
Gross profit
$113M
Operating income
-$37.4M
EBITDA
-$2.3M
Net income
-$33.6M
EPS
-$1.62
Total assets
$646M
Total debt
$5.6M
Gross margin
52.48%
Net margin
-15.64%
Earnings yield
-12.67%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

11.0112.6314.2515.8717.49
AMRN 1D NASDAQ O12.20H13.01L12.10C12.79+0.84 (+6.99%)Vol56.02K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
AMRNAmarin Corporation plc Stock news Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript Seeking Alpha
AMRNAmarin Corporation plc Stock news What Amarin (AMRN) Said on Its Q3 Earnings Call MarketBeat
AMRNAmarin Corporation plc Press release Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income GlobeNewswire
AMRNAmarin Corporation plc Press release Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colore. GlobeNewswire
AMRNAmarin Corporation plc Press release Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 GlobeNewswire
AMRNAmarin Corporation plc Stock news Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) Defense World
AMRNAmarin Corporation plc Stock news Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
AMRNAmarin Corporation plc Press release Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 GlobeNewsWire
AMRNAmarin Corporation plc Press release New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients GlobeNewsWire
AMRNAmarin Corporation plc Press release New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 GlobeNewsWire
AMRNAmarin Corporation plc Stock news Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? Zacks Investment Research
AMRNAmarin Corporation plc Press release Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 GlobeNewsWire
AMRNAmarin Corporation plc Stock news Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now Zacks Investment Research
AMRNAmarin Corporation plc Press release Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape GlobeNewsWire
AMRNAmarin Corporation plc Press release New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia GlobeNewsWire
AMRNAmarin Corporation plc Stock news IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13% Zacks Investment Research
AMRNAmarin Corporation plc Stock news All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy Zacks Investment Research
AMRNAmarin Corporation plc Stock news Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y Zacks Investment Research
AMRNAmarin Corporation plc Stock news Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript Seeking Alpha
AMRNAmarin Corporation plc Press release Amarin Reports 2026 First Quarter Financial Results GlobeNewsWire
See more
FAQ

Questions about Amarin Corporation plc

What does Amarin Corporation plc do?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
What is AMRN's market cap?
Amarin Corporation plc (AMRN) is a listed stock with a live quote. The latest market cap on this page is $264M.
Where is Amarin Corporation plc headquartered?
Amarin Corporation plc is headquartered in Dublin.
How do I get AMRN news from the API?
Call GET /v1/news?tickers=AMRN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does AMRN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AMRN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the AMRN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs